BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Management of HCC. Journal of Hepatology 2012;56:S75-87. [DOI: 10.1016/s0168-8278(12)60009-9] [Cited by in Crossref: 363] [Cited by in F6Publishing: 196] [Article Influence: 40.3] [Reference Citation Analysis]
Number Citing Articles
1 Hou JK, Huang Y, He W, Yan ZW, Fan L, Liu MH, Xiao WL, Sun HD, Chen GQ. Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells. Cell Death Dis. 2014;5:e1400. [PMID: 25188510 DOI: 10.1038/cddis.2014.345] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
2 Lee GC, Ferrone CR, Vagefi PA, Uppot RN, Tanabe KK, Lillemoe KD, Blaszkowsky LS, Qadan M. Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. Am J Surg 2019;218:157-63. [PMID: 30635211 DOI: 10.1016/j.amjsurg.2018.12.067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX, Huang ZY, Chen YF, Zhang WG, Luo HP, Chen Q, Chen XP. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer 2018;18:835. [PMID: 30126375 DOI: 10.1186/s12885-018-4744-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
4 Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer 2013;4:635-43. [PMID: 24155775 DOI: 10.7150/jca.7279] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
5 Lee YH, Hsu CY, Chu CW, Liu PH, Hsia CY, Huang YH, Su CW, Chiou YY, Lin HC, Huo TI. A new Child-Turcotte-Pugh class 0 for patients with hepatocellular carcinoma: determinants, prognostic impact and ability to improve the current staging systems. PLoS One 2014;9:e99115. [PMID: 24906132 DOI: 10.1371/journal.pone.0099115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
6 Sheth RA, Heidari P, Esfahani SA, Wood BJ, Mahmood U. Interventional optical molecular imaging guidance during percutaneous biopsy. Radiology 2014;271:770-7. [PMID: 24520946 DOI: 10.1148/radiol.14131880] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
7 Memeo R, de Blasi V, Cherkaoui Z, Dehlawi A, De' Angelis N, Piardi T, Sommacale D, Marescaux J, Mutter D, Pessaux P. New Approaches in Locoregional Therapies for Hepatocellular Carcinoma. J Gastrointest Cancer 2016;47:239-46. [PMID: 27270711 DOI: 10.1007/s12029-016-9840-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Ha Y, Lee JB, Shim JH, Kim KM, Lim YS, Yoon HK, Shin YM, Lee HC. Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. Eur Radiol 2016;26:3510-8. [PMID: 26747261 DOI: 10.1007/s00330-015-4185-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
9 Raoul JL, Gilabert M, Piana G. How to define transarterial chemoembolization failure or refractoriness: a European perspective. Liver Cancer 2014;3:119-24. [PMID: 24945002 DOI: 10.1159/000343867] [Cited by in Crossref: 39] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
10 Zhang H, Yuan SX, Dai SY, Zhang JM, Huang X, Lu CD, Lu JH, Wu FQ, Lau WY, Wu MC, Yang T, Shen F. Tumor size does not independently affect long-term survival after curative resection of solitary hepatocellular carcinoma without macroscopic vascular invasion. World J Surg 2014;38:947-57. [PMID: 24258262 DOI: 10.1007/s00268-013-2365-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.9] [Reference Citation Analysis]
11 Ohata T, Yokoo H, Kamiyama T, Fukai M, Aiyama T, Hatanaka Y, Hatanaka K, Wakayama K, Orimo T, Kakisaka T, Kobayashi N, Matsuno Y, Taketomi A. Fatty acid-binding protein 5 function in hepatocellular carcinoma through induction of epithelial-mesenchymal transition. Cancer Med 2017;6:1049-61. [PMID: 28374947 DOI: 10.1002/cam4.1020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
12 Su CW, Chiou YW, Tsai YH, Teng RD, Chau GY, Lei HJ, Hung HH, Huo TI, Wu JC. The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. PLoS One. 2013;8:e66457. [PMID: 23805222 DOI: 10.1371/journal.pone.0066457] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
13 Cao Z, Fu B, Deng B, Zeng Y, Wan X, Qu L. Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma. Cancer Cell Int 2014;14:86. [PMID: 25298747 DOI: 10.1186/s12935-014-0086-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
14 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zeng ZC, Seong J, Yoon SM, Cheng JC, Lam KO, Lee AS, Law A, Zhang JY, Hu Y. Consensus on Stereotactic Body Radiation Therapy for Small-Sized Hepatocellular Carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017;6:264-274. [PMID: 29234630 DOI: 10.1159/000475768] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
16 Hu P, Fu Z, Liu G, Tan H, Xiao J, Shi H, Cheng D. Gadolinium-Based Nanoparticles for Theranostic MRI-Guided Radiosensitization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2019;7:368. [PMID: 31828068 DOI: 10.3389/fbioe.2019.00368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
17 Ito T, Kumada T, Toyoda H, Tada T. FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol. 2015;141:1311-1319. [PMID: 25648362 DOI: 10.1007/s00432-015-1922-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
18 Ng KJ, Tseng CW, Chang TT, Tzeng SJ, Hsieh YH, Hung TH, Huang HT, Wu SF, Tseng KC. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. Clin Interv Aging. 2016;11:1035-1041. [PMID: 27536084 DOI: 10.2147/cia.s108589] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
19 Bai J, Wu J, Tang R, Sun C, Ji J, Yin Z, Ma G, Yang W. Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a. Invest New Drugs. 2020;38:229-245. [PMID: 30976957 DOI: 10.1007/s10637-019-00777-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
20 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
21 Kang WH, Kim KH, Jung DH, Park GC, Kim SH, Cho HD, Lee SG. Long-term results of laparoscopic liver resection for the primary treatment of hepatocellular carcinoma: role of the surgeon in anatomical resection. Surg Endosc 2018;32:4481-90. [PMID: 29691651 DOI: 10.1007/s00464-018-6194-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
22 Wang Q, Fiel MI, Blank S, Luan W, Kadri H, Kim KW, Manizate F, Rosenblatt AG, Labow DM, Schwartz ME. Impact of liver fibrosis on prognosis following liver resection for hepatitis B-associated hepatocellular carcinoma. Br J Cancer. 2013;109:573-581. [PMID: 23846171 DOI: 10.1038/bjc.2013.352] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 5.5] [Reference Citation Analysis]
23 Zhang ZQ, Xiong L, Zhou JJ, Miao XY, Li QL, Wen Y, Zou H. Ability of the ALBI grade to predict posthepatectomy liver failure and long-term survival after liver resection for different BCLC stages of HCC. World J Surg Oncol. 2018;16:208. [PMID: 30326907 DOI: 10.1186/s12957-018-1500-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
24 De Minicis S, Marzioni M, Benedetti A, Svegliati-Baroni G. New insights in hepatocellular carcinoma: from bench to bedside. Ann Transl Med 2013;1:15. [PMID: 25332959 DOI: 10.3978/j.issn.2305-5839.2013.01.06] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
25 Xiong F, Zhang F, Jin Y, Weng Q, Song J, Zhou G, Shin D, Zheng C, Yang X. Orthotopic hepatic cancer: radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy. Oncotarget 2018;9:14099-108. [PMID: 29581830 DOI: 10.18632/oncotarget.23586] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Kang D, Shim S, Cho J, Lim HK. Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018. Korean J Radiol 2020;21:633-46. [PMID: 32410403 DOI: 10.3348/kjr.2019.0808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Bürger C, Maschmeier M, Hüsing-Kabar A, Wilms C, Köhler M, Schmidt M, Schmidt HH, Kabar I. Achieving Complete Remission of Hepatocellular Carcinoma: A Significant Predictor for Recurrence-Free Survival after Liver Transplantation. Can J Gastroenterol Hepatol 2019;2019:5796074. [PMID: 30729099 DOI: 10.1155/2019/5796074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Nishikawa H, Kita R, Kimura T, Ohara Y, Takeda H, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: Clinical outcome and safety in elderly patients. J Cancer. 2014;5:590-597. [PMID: 25057310 DOI: 10.7150/jca.9413] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
29 Molla N, AlMenieir N, Simoneau E, Aljiffry M, Valenti D, Metrakos P, Boucher LM, Hassanain M. The role of interventional radiology in the management of hepatocellular carcinoma. Curr Oncol. 2014;21:e480-e492. [PMID: 24940108 DOI: 10.3747/co.21.1829] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
30 Hou YF, Wei YG, Li B, Yang JY, Wen TF, Xu MQ, Yan LN, Wang WT. Upper abdominal shape as a risk factor of extended operation time and severe postoperative complications in HCC hepatectomy through subcostal incision. World J Surg Oncol 2015;13:298. [PMID: 26462559 DOI: 10.1186/s12957-015-0702-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
31 Nishikawa H, Nishijima N, Arimoto A, Inuzuka T, Kita R, Kimura T, Osaki Y. Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy. Oncol Lett. 2013;6:1213-1218. [PMID: 24179497 DOI: 10.3892/ol.2013.1578] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
32 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 6.8] [Reference Citation Analysis]
33 Jin R, Lin H, Li G, Xu J, Shi L, Chang C, Cai X. TR4 nuclear receptor suppresses HCC cell invasion via downregulating the EphA2 expression. Cell Death Dis 2018;9:283. [PMID: 29449527 DOI: 10.1038/s41419-018-0287-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
34 Rodríguez de Lope C, Reig ME, Darnell A, Forner A. Approach of the patient with a liver mass. Frontline Gastroenterol 2012;3:252-62. [PMID: 28839677 DOI: 10.1136/flgastro-2012-100146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Azumi J, Tsubota T, Sakabe T, Shiota G. miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression. Cancer Sci 2016;107:1256-62. [PMID: 27384977 DOI: 10.1111/cas.13006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
36 Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection. J Gastrointest Surg. 2013;17:702-711. [PMID: 23225107 DOI: 10.1007/s11605-012-2087-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
37 Tarantino G, Magistri P, Ballarin R, Di Francia R, Berretta M, Di Benedetto F. Oncological Impact of M-Tor Inhibitor Immunosuppressive Therapy after Liver Transplantation for Hepatocellular Carcinoma: Review of the Literature. Front Pharmacol 2016;7:387. [PMID: 27818634 DOI: 10.3389/fphar.2016.00387] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
38 Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, Zhang K, Ye Z, Wang C, Yang H. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2015;30:131-8. [PMID: 24995497 DOI: 10.1111/jgh.12664] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
39 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Reference Citation Analysis]
40 Park ER, Kim SB, Lee JS, Kim YH, Lee DH, Cho EH, Park SH, Han CJ, Kim BY, Choi DW, Yoo YD, Yu A, Lee JW, Jang JJ, Park YN, Suh KS, Lee KH. The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma. Cancer Med 2017;6:749-60. [PMID: 28332314 DOI: 10.1002/cam4.1042] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
41 Abboud S, Raparia K, Ubago JM, Resnick S. AngioVac extraction of intra-atrial hepatoma masquerading as PICC-associated thrombus. Diagn Interv Radiol 2016;22:72-4. [PMID: 26509915 DOI: 10.5152/dir.2015.15243] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
42 Elsharkawy AM, Hudson M. The future developments in hepatology: no need for a jaundiced view. Frontline Gastroenterol 2012;3:i47-52. [PMID: 28839693 DOI: 10.1136/flgastro-2012-100153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Moschitto MJ, Doubleday PF, Catlin DS, Kelleher NL, Liu D, Silverman RB. Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid. J Am Chem Soc 2019;141:10711-21. [PMID: 31251613 DOI: 10.1021/jacs.9b03254] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 Lee D, Lee HC, An J, Shim JH, Kim KM, Lim YS, Chung YH, Lee YS. Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. Clin Mol Hepatol 2018;24:144-50. [PMID: 29665630 DOI: 10.3350/cmh.2017.0041] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
45 Surov A, Pech M, Omari J, Fischbach F, Damm R, Fischbach K, Powerski M, Relja B, Wienke A. Diffusion-Weighted Imaging Reflects Tumor Grading and Microvascular Invasion in Hepatocellular Carcinoma. Liver Cancer 2021;10:10-24. [PMID: 33708636 DOI: 10.1159/000511384] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Groeschl RT, Hong JC, Christians KK, Turaga KK, Tsai S, Pilgrim CH, Gamblin TC. Viral status at the time of liver transplantation for hepatocellular carcinoma: a modern predictor of longterm survival. HPB (Oxford) 2013;15:794-802. [PMID: 23782341 DOI: 10.1111/hpb.12134] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Gomaa AI, Waked I. Recent advances in multidisciplinary management of hepatocellular carcinoma. World J Hepatol 2015; 7(4): 673-687 [PMID: 25866604 DOI: 10.4254/wjh.v7.i4.673] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 9.7] [Reference Citation Analysis]
48 Takata H, Kudo M, Yamamoto T, Ueda J, Ishino K, Peng WX, Wada R, Taniai N, Yoshida H, Uchida E, Naito Z. Increased expression of PDIA3 and its association with cancer cell proliferation and poor prognosis in hepatocellular carcinoma. Oncol Lett 2016;12:4896-904. [PMID: 28101228 DOI: 10.3892/ol.2016.5304] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
49 Wang C, Zhou X, Xu H, Shi X, Zhao J, Yang M, Zhang L, Jin X, Hu Y, Li X, Xiao X, Liao M. Niclosamide Inhibits Cell Growth and Enhances Drug Sensitivity of Hepatocellular Carcinoma Cells via STAT3 Signaling Pathway. J Cancer 2018;9:4150-5. [PMID: 30519314 DOI: 10.7150/jca.26948] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
50 Zhao JB, Feng C, Zhu QH, He XF, Li YH, Chen Y. Transjugular intrahepatic portosystemic shunt with covered stents for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2014; 20(6): 1602-1607 [PMID: 24587637 DOI: 10.3748/wjg.v20.i6.1602] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
51 Tampaki M, Doumba PP, Deutsch M, Koskinas J. Circulating biomarkers of hepatocellular carcinoma response after locoregional treatments: New insights. World J Hepatol 2015; 7(14): 1834-1842 [PMID: 26207165 DOI: 10.4254/wjh.v7.i14.1834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
52 Zheng X, Ma W, Sun R, Yin H, Lin F, Liu Y, Xu W, Zeng H. Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity. Redox Biol 2018;14:237-49. [PMID: 28965082 DOI: 10.1016/j.redox.2017.09.014] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
53 Fahrner R, Dondorf F, Ardelt M, Dittmar Y, Settmacher U, Rauchfuß F. Liver transplantation for hepatocellular carcinoma - factors influencing outcome and disease-free survival. World J Gastroenterol 2015; 21(42): 12071-12082 [PMID: 26576092 DOI: 10.3748/wjg.v21.i42.12071] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
54 Zhu D, Wu ZH, Xu L, Yang DL. Single sample scoring of hepatocellular carcinoma: A study based on data mining. Int J Immunopathol Pharmacol 2021;35:20587384211018389. [PMID: 34053310 DOI: 10.1177/20587384211018389] [Reference Citation Analysis]
55 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Maeda H, Matsuo K, Nishida N, Aramaki T, Anai H, Koura S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-5. [PMID: 24615165 DOI: 10.1007/s11604-014-0298-9] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
56 Fuster J. Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification? Hepat Oncol 2015;2:245-53. [PMID: 30191006 DOI: 10.2217/hep.15.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:394-402. [PMID: 25767611 DOI: 10.7150/jca.11212] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
58 Xia Y, Li J, Liu G, Wang K, Qian G, Lu Z, Yang T, Yan Z, Lei Z, Si A, Wan X, Zhang H, Gao C, Cheng Z, Pawlik TM, Wang H, Lau WY, Wu M, Shen F. Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2019;. [PMID: 31774468 DOI: 10.1001/jamaoncol.2019.4477] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
59 Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017;17:896. [PMID: 29282035 DOI: 10.1186/s12885-017-3911-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
60 Mao X, Du S, Yang Z, Zhang L, Peng X, Jiang N, Zhou H. Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro. Mol Med Rep 2017;16:208-14. [PMID: 28498459 DOI: 10.3892/mmr.2017.6568] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
61 Patella F, Pesapane F, Fumarola EM, Emili I, Spairani R, Angileri SA, Tresoldi S, Franceschelli G, Carrafiello G. CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners. J Clin Transl Hepatol 2018;6:222-36. [PMID: 29951368 DOI: 10.14218/JCTH.2017.00062] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
62 Demir M, Grünewald F, Lang S, Schramm C, Bowe A, Mück V, Kütting F, Goeser T, Steffen HM. Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients. Medicine (Baltimore) 2016;95:e4602. [PMID: 27661015 DOI: 10.1097/MD.0000000000004602] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Yang T, Lau WY, Zhang H, Huang B, Lu JH, Wu MC. Grey zone in the Barcelona Clinic Liver Cancer Classification for hepatocellular carcinoma: Surgeons’ perspective. World J Gastroenterol 2015; 21(27): 8256-8261 [PMID: 26217077 DOI: 10.3748/wjg.v21.i27.8256] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
64 Wang YG, Wang P, Wang B, Fu ZJ, Zhao WJ, Yan SL. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014;9:e95485. [PMID: 24830459 DOI: 10.1371/journal.pone.0095485] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
65 Zheng J, Xie W, Huang Y, Zhu Y, Jiang L. The technique of 3D reconstruction combining with biochemistry to build an equivalent formula of indocyanine green (ICG) clearance test to assess the liver reserve function. BMC Surg 2020;20:283. [PMID: 33183305 DOI: 10.1186/s12893-020-00952-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Nishikawa H, Osaki Y. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. J Cancer 2013;4:473-80. [PMID: 23901347 DOI: 10.7150/jca.6609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
67 Wei F, Huang Q, Zhou Y, Luo L, Zeng Y. Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study. World J Surg Oncol 2021;19:175. [PMID: 34127007 DOI: 10.1186/s12957-021-02277-4] [Reference Citation Analysis]
68 Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer 2012;1:144-58. [PMID: 24159579 DOI: 10.1159/000343828] [Cited by in Crossref: 169] [Cited by in F6Publishing: 170] [Article Influence: 24.1] [Reference Citation Analysis]
69 Yoon HI, Jung I, Han KH, Seong J. The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma. Oncotarget 2016;7:62715-25. [PMID: 27486881 DOI: 10.18632/oncotarget.10908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
70 Chen J, Wu M, Liu R, Li S, Gao R, Song B. Preoperative evaluation of the histological grade of hepatocellular carcinoma with diffusion-weighted imaging: a meta-analysis. PLoS One 2015;10:e0117661. [PMID: 25658359 DOI: 10.1371/journal.pone.0117661] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
71 Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016; 22(27): 6100-6113 [PMID: 27468203 DOI: 10.3748/wjg.v22.i27.6100] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
72 Nishikawa H, Kita R, Kimura T, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Osaki Y. Hyponatremia in hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015;6:482-9. [PMID: 25874013 DOI: 10.7150/jca.11665] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
73 Sun X, Zhang Y, Lyu N, Li X, Chen M, Zhao M. The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up? Med Sci Monit 2019;25:4941-51. [PMID: 31270311 DOI: 10.12659/MSM.916451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G. Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer. 2013;12:162. [PMID: 24330766 DOI: 10.1186/1476-4598-12-162] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
75 Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587 [PMID: 25253961 DOI: 10.3748/wjg.v20.i35.12581] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
76 He ZX, Xiang P, Gong JP, Cheng NS, Zhang W. Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review. Ther Clin Risk Manag 2016;12:295-303. [PMID: 26966370 DOI: 10.2147/TCRM.S96760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
77 He X, Liu F, Yan J, Zhang Y, Yan J, Shang H, Dou Q, Zhao Q, Song Y. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo. Sci Rep 2015;5:8705. [PMID: 25732051 DOI: 10.1038/srep08705] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
78 Wang JP, Yao ZG, Sun YW, Liu XH, Sun FK, Lin CH, Ren FX, Lv BB, Zhang SJ, Wang Y, Meng FY, Zheng SZ, Gong W, Liu J. Clinicopathological characteristics and surgical outcomes of sarcomatoid hepatocellular carcinoma. World J Gastroenterol 2020; 26(29): 4327-4342 [PMID: 32848337 DOI: 10.3748/wjg.v26.i29.4327] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
79 Liu P, Lee Y, Hsu C, Hsia C, Huang Y, Chiou Y, Lin H, Huo T. Surgical Resection Is Better than Transarterial Chemoembolization for Hepatocellular Carcinoma Beyond Milan Criteria Independent of Performance Status. J Gastrointest Surg 2014;18:1623-31. [DOI: 10.1007/s11605-014-2546-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
80 Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2016;5:e1083671. [PMID: 27141337 DOI: 10.1080/2162402x.2015.1083671] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
81 Sapisochin G, Sevilla EF, Echeverri J, Charco R. Management of “very early” hepatocellular carcinoma on cirrhotic patients. World J Hepatol 2014; 6(11): 766-775 [PMID: 25429314 DOI: 10.4254/wjh.v6.i11.766] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
82 Zhu W, Doubleday PF, Catlin DS, Weerawarna PM, Butrin A, Shen S, Wawrzak Z, Kelleher NL, Liu D, Silverman RB. A Remarkable Difference That One Fluorine Atom Confers on the Mechanisms of Inactivation of Human Ornithine Aminotransferase by Two Cyclohexene Analogues of γ-Aminobutyric Acid. J Am Chem Soc 2020;142:4892-903. [PMID: 32114761 DOI: 10.1021/jacs.0c00193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
83 Nishikawa H, Takeda H, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Osaki Y, Izumi N; Japanese Red Cross Liver Study Group. Sorafenib Therapy for BCLC Stage B/C Hepatocellular Carcinoma; Clinical Outcome and Safety in Aged Patients: A Multicenter Study in Japan. J Cancer 2014;5:499-509. [PMID: 24963354 DOI: 10.7150/jca.9257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
84 Tao CY, Liu WR, Jin L, Tang Z, Tian MX, Jiang XF, Wang H, Zhou PY, Fang Y, Ding ZB, Peng YF, Dai Z, Qiu SJ, Zhou J, Fan J, Shi YH. Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. J Cancer 2018;9:1106-12. [PMID: 29581790 DOI: 10.7150/jca.23921] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
85 Yoon YI, Hwang S, Lee YJ, Kim KH, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Lee JW. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Gastrointest Surg. 2016;20:411-420. [PMID: 26628072 DOI: 10.1007/s11605-015-3045-3] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 8.2] [Reference Citation Analysis]
86 Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8. [PMID: 23635789 DOI: 10.1172/JCI66024] [Cited by in Crossref: 310] [Cited by in F6Publishing: 221] [Article Influence: 38.8] [Reference Citation Analysis]
87 Simon K, Serafińska S, Pazgan-Simon M. Surveillance programmes for early detection of hepatocellular carcinoma. Contemp Oncol (Pozn) 2012;16:295-9. [PMID: 23788898 DOI: 10.5114/wo.2012.30057] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14:203-217. [PMID: 28053342 DOI: 10.1038/nrgastro.2016.193] [Cited by in Crossref: 146] [Cited by in F6Publishing: 144] [Article Influence: 36.5] [Reference Citation Analysis]
89 Wang M, Gao Y, Feng H, Warner E, An M, Jia J, Chen S, Fang M, Ji J, Gu X, Gao C. A nomogram incorporating six easily obtained parameters to discriminate intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Cancer Med 2018;7:646-54. [PMID: 29473340 DOI: 10.1002/cam4.1341] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
90 Jiang B, Zhang R, Zhang J, Hou Y, Chen X, Zhou M, Tian X, Hao C, Fan K, Yan X. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy. Theranostics 2019;9:2167-82. [PMID: 31149036 DOI: 10.7150/thno.30867] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 18.0] [Reference Citation Analysis]
91 Lacaze L, Scotté M. Surgical treatment of intra hepatic recurrence of hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1755-1760 [PMID: 26167248 DOI: 10.4254/wjh.v7.i13.1755] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
92 Liu H, Wan Z, She L, Zhu Y, Cai Z, Wu B, Zhuang Q, Ke P, Wu X, Li Z, Huang X. Inflammation Pharmacological Reaction and YMDD Mutational Patterns in Lamivudine Therapeutics Hepatitis B Virus. Front Pharmacol 2021;12:648170. [PMID: 33935748 DOI: 10.3389/fphar.2021.648170] [Reference Citation Analysis]
93 Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, Yamamoto S, Matsuo K, Nishida N, Aramaki T, Anai H, Kora S, Oikawa S, Watanabe K, Yasumoto T, Furuichi K, Yamaguchi M. Prognosis of patients with intermediate-stage hepatocellular carcinomas based on the Child-Pugh score: subclassifying the intermediate stage (Barcelona Clinic Liver Cancer stage B). Jpn J Radiol 2014;32:644-9. [DOI: 10.1007/s11604-014-0358-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
94 Chen J, Sheu AY, Li W, Zhang Z, Kim DH, Lewandowski RJ, Omary RA, Shea LD, Larson AC. Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors. J Control Release 2014;184:10-7. [PMID: 24727059 DOI: 10.1016/j.jconrel.2014.04.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.7] [Reference Citation Analysis]
95 Iwahashi S, Ghaibeh AA, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, Hirose J. Predictability of postoperative recurrence on hepatocellular carcinoma through data mining method. Mol Clin Oncol 2020;13:46. [PMID: 32874576 DOI: 10.3892/mco.2020.2116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
96 Shimagaki T, Yoshio S, Kawai H, Sakamoto Y, Doi H, Matsuda M, Mori T, Osawa Y, Fukai M, Yoshida T, Ma Y, Akita T, Tanaka J, Taketomi A, Hanayama R, Yoshizumi T, Mori M, Kanto T. Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Sci Rep. 2019;9:15788. [PMID: 31673081 DOI: 10.1038/s41598-019-52356-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
97 Lu M, Hu XH, Li Q, Xiong Y, Hu GJ, Xu JJ, Zhao XN, Wei XX, Chang CC, Liu YK, Nan FJ, Li J, Chang TY, Song BL, Li BL. A specific cholesterol metabolic pathway is established in a subset of HCCs for tumor growth. J Mol Cell Biol 2013;5:404-15. [PMID: 24163426 DOI: 10.1093/jmcb/mjt039] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
98 Yamashita T, Kitao A, Matsui O, Hayashi T, Nio K, Kondo M, Ohno N, Miyati T, Okada H, Yamashita T, Mizukoshi E, Honda M, Nakanuma Y, Takamura H, Ohta T, Nakamoto Y, Yamamoto M, Takayama T, Arii S, Wang X, Kaneko S. Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology. 2014;60:1674-1685. [PMID: 24700365 DOI: 10.1002/hep.27093] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 9.7] [Reference Citation Analysis]
99 Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
100 Dou Y, van Montfoort N, van den Bosch A, Janssen HLA, de Man RA, Buschow SI, Woltman AM. Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response. J Viral Hepat 2019;26:1076-85. [PMID: 31090247 DOI: 10.1111/jvh.13127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Ye HH, Ye JZ, Xie ZB, Peng YC, Chen J, Ma L, Bai T, Chen JZ, Lu Z, Qin HG, Xiang BD, Li LQ. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein. World J Gastroenterol 2016; 22(13): 3632-3643 [PMID: 27053855 DOI: 10.3748/wjg.v22.i13.3632] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Foltz G. Image-guided percutaneous ablation of hepatic malignancies. Semin Intervent Radiol. 2014;31:180-186. [PMID: 25071304 DOI: 10.1055/s-0034-1373792] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
103 Yang D, Zhuang B, Wang Y, Xie X, Xie X. Radiofrequency ablation versus hepatic resection for recurrent hepatocellular carcinoma: an updated meta-analysis. BMC Gastroenterol 2020;20:402. [PMID: 33246417 DOI: 10.1186/s12876-020-01544-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Chen JH, Wei CK, Lee CH, Chang CM, Hsu TW, Yin WY. The safety and adequacy of resection on hepatocellular carcinoma larger than 10 cm: A retrospective study over 10 years. Ann Med Surg (Lond) 2015;4:193-9. [PMID: 26052436 DOI: 10.1016/j.amsu.2015.05.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
105 Girotra M, Soota K, Dhaliwal AS, Abraham RR, Garcia-Saenz-de-Sicilia M, Tharian B. Utility of endoscopic ultrasound and endoscopy in diagnosis and management of hepatocellular carcinoma and its complications: What does endoscopic ultrasonography offer above and beyond conventional cross-sectional imaging? World J Gastrointest Endosc 2018; 10(2): 56-68 [PMID: 29467916 DOI: 10.4253/wjge.v10.i2.56] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
106 Joo I, Lee JM. Recent Advances in the Imaging Diagnosis of Hepatocellular Carcinoma: Value of Gadoxetic Acid-Enhanced MRI. Liver Cancer 2016;5:67-87. [PMID: 26989660 DOI: 10.1159/000367750] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
107 Gao L, Zhang J, Ma T, Yao N, Gao M, Shan X, Ni Y, Shao H, Xu K. Improved therapeutic outcomes of thermal ablation on rat orthotopic liver allograft sarcoma models by radioiodinated hypericin induced necrosis targeted radiotherapy. Oncotarget 2016;7:51450-61. [PMID: 27285983 DOI: 10.18632/oncotarget.9848] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
108 Nishikawa H, Arimoto A, Wakasa T, Kita R, Kimura T, Osaki Y. The Relation between Obesity and Survival after Surgical Resection of Hepatitis C Virus-Related Hepatocellular Carcinoma. Gastroenterol Res Pract 2013;2013:430438. [PMID: 23710167 DOI: 10.1155/2013/430438] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
109 Desiderio J, Trastulli S, Pasquale R, Cavaliere D, Cirocchi R, Boselli C, Noya G, Parisi A. Could radiofrequency ablation replace liver resection for small hepatocellular carcinoma in patients with compensated cirrhosis? A 5-year follow-up. Langenbecks Arch Surg 2013;398:55-62. [PMID: 23224564 DOI: 10.1007/s00423-012-1029-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
110 Sirohi B, Shrikhande SV, Gaikwad V, Patel A, Patkar S, Goel M, Bal M, Sharma A, Shrimali RK, Bhatia V, Kulkarni S, Srivastava DN, Kaur T, Dhaliwal RS, Rath GK; Indian Council of Medical Research Guidelines Working Group. Indian Council of Medical Research consensus document on hepatocellular carcinoma. Indian J Med Res 2020;152:468-74. [PMID: 33707388 DOI: 10.4103/ijmr.IJMR_404_20] [Reference Citation Analysis]
111 Ni HM, Williams JA, Yang H, Shi YH, Fan J, Ding WX. Targeting autophagy for the treatment of liver diseases. Pharmacol Res 2012;66:463-74. [PMID: 22871337 DOI: 10.1016/j.phrs.2012.07.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 5.0] [Reference Citation Analysis]
112 Xiao S, Liu L, Fang M, Zhou X, Peng X, Long J, Lu X. BPTF Associated with EMT Indicates Negative Prognosis in Patients with Hepatocellular Carcinoma. Dig Dis Sci 2015;60:910-8. [PMID: 25362514 DOI: 10.1007/s10620-014-3411-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
113 Esfahani SA, Heidari P, Kim SA, Ogino S, Mahmood U. Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors. Theranostics 2016;6:2028-38. [PMID: 27698938 DOI: 10.7150/thno.15718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
114 Schraml C, Kaufmann S, Rempp H, Syha R, Ketelsen D, Notohamiprodjo M, Nikolaou K. Imaging of HCC-Current State of the Art. Diagnostics (Basel). 2015;5:513-545. [PMID: 26854169 DOI: 10.3390/diagnostics5040513] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
115 Yu HP, Xie JM, Li B, Sun YH, Gao QG, Ding ZH, Wu HR, Qin ZH. TIGAR regulates DNA damage and repair through pentosephosphate pathway and Cdk5-ATM pathway. Sci Rep 2015;5:9853. [PMID: 25928429 DOI: 10.1038/srep09853] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
116 Wang W, Gu D, Wei J, Ding Y, Yang L, Zhu K, Luo R, Rao SX, Tian J, Zeng M. A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid-enhanced MRI. Eur Radiol. 2020;30:3004-3014. [PMID: 32002645 DOI: 10.1007/s00330-019-06585-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
117 Yu J, Yu XL, Han ZY, Cheng ZG, Liu FY, Zhai HY, Mu MJ, Liu YM, Liang P. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomised controlled trial. Gut 2017;66:1172-3. [PMID: 27884919 DOI: 10.1136/gutjnl-2016-312629] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 12.4] [Reference Citation Analysis]
118 Shek FH, Fatima S, Lee NP. Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma. Int J Hepatol 2012;2012:760928. [PMID: 23029619 DOI: 10.1155/2012/760928] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
119 Hu B, Jiang D, Chen Y, Wei L, Zhang S, Zhao F, Ni R, Lu C, Wan C. High CHMP4B expression is associated with accelerated cell proliferation and resistance to doxorubicin in hepatocellular carcinoma. Tumour Biol 2015;36:2569-81. [PMID: 25874485 DOI: 10.1007/s13277-014-2873-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
120 Giannini EG, Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: How best to do it? World J Gastroenterol 2013; 19(47): 8808-8821 [PMID: 24379604 DOI: 10.3748/wjg.v19.i47.8808] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
121 Xu LL, Zhang M, Yi PS, Zheng XB, Feng L, Lan C, Tang JW, Ren SS, Xu MQ. Hepatic resection combined with radiofrequency ablation versus hepatic resection alone for multifocal hepatocellular carcinomas: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 2017;37:974-980. [PMID: 29270762 DOI: 10.1007/s11596-017-1836-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Sun H, Zhu MS, Wu WR, Shi XD, Xu LB. Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out. World J Hepatol 2014; 6(12): 830-835 [PMID: 25544869 DOI: 10.4254/wjh.v6.i12.830] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
123 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
124 Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014;63:844-855. [PMID: 24531850 DOI: 10.1136/gutjnl-2013-306627] [Cited by in Crossref: 790] [Cited by in F6Publishing: 802] [Article Influence: 112.9] [Reference Citation Analysis]
125 Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, Weiss MJ, He J, Philosophe B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. JCI Insight 2021;6:138197. [PMID: 34003798 DOI: 10.1172/jci.insight.138197] [Reference Citation Analysis]
126 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
127 Hung HH, Chao Y, Chiou YY, Li CP, Lee RC, Huo TI, Huang YH, Chau GY, Su CW, Yeh YC, Lin HC, Lee SD, Wu JC. A comparison of clinical manifestations and prognoses between patients with hepatocellular carcinoma and Child-Pugh scores of 5 or 6. Medicine (Baltimore) 2014;93:e348. [PMID: 25546689 DOI: 10.1097/MD.0000000000000348] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
128 Lee JW, Hwang SH, Kim HJ, Kim D, Cho A, Yun M. Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection. Eur J Nucl Med Mol Imaging. 2017;44:1984-1994. [PMID: 28695236 DOI: 10.1007/s00259-017-3764-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
129 Adhoute X, Penaranda G, Castellani P, Perrier H, Bourliere M. Recommendations for the use of chemoembolization in patients with hepatocellular carcinoma: Usefulness of scoring system? World J Hepatol 2015; 7(3): 521-531 [PMID: 25848475 DOI: 10.4254/wjh.v7.i3.521] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
130 Cucchetti A, Cescon M, Trevisani F, Pinna AD. Current concepts in hepatic resection for hepatocellular carcinoma in cirrhotic patients. World J Gastroenterol 2012; 18(44): 6398-6408 [PMID: 23197885 DOI: 10.3748/wjg.v18.i44.6398] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
131 Xiao Y, Lin M, Jiang X, Ye J, Guo T, Shi Y, Bian X. The Recent Advances on Liver Cancer Stem Cells: Biomarkers, Separation, and Therapy. Anal Cell Pathol (Amst) 2017;2017:5108653. [PMID: 28819584 DOI: 10.1155/2017/5108653] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
132 Liu YY, Zheng Q, Fang B, Wang W, Ma FY, Roshan S, Banafa A, Chen MJ, Chang JL, Deng XM. Germacrone induces apoptosis in human hepatoma HepG2 cells through inhibition of the JAK2/STAT3 signalling pathway. J Huazhong Univ Sci Technolog Med Sci. 2013;33:339-345. [PMID: 23771657 DOI: 10.1007/s11596-013-1121-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
133 Tarocchi M, Polvani S, Peired AJ, Marroncini G, Calamante M, Ceni E, Rhodes D, Mello T, Pieraccini G, Quattrone A. Telomerase activated thymidine analogue pro-drug is a new molecule targeting hepatocellular carcinoma. J Hepatol. 2014;61:1064-1072. [PMID: 24862448 DOI: 10.1016/j.jhep.2014.05.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
134 Zhong JH, Li H, Xiao N, Ye XP, Ke Y, Wang YY, Ma L, Chen J, You XM, Zhang ZY, Lu SD, Li LQ. Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension. PLoS One. 2014;9:e108755. [PMID: 25268959 DOI: 10.1371/journal.pone.0108755] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
135 Bacigalupo ML, Carabias P, Troncoso MF. Contribution of galectin-1, a glycan-binding protein, to gastrointestinal tumor progression. World J Gastroenterol 2017; 23(29): 5266-5281 [PMID: 28839427 DOI: 10.3748/wjg.v23.i29.5266] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
136 Lu L, Zhou J, Shi J, Peng XJ, Qi XX, Wang Y, Li FY, Zhou FY, Liu L, Liu ZQ. Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients. PLoS One 2015;10:e0127524. [PMID: 26010150 DOI: 10.1371/journal.pone.0127524] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
137 Sastre J, Díaz-Beveridge R, García-Foncillas J, Guardeño R, López C, Pazo R, Rodriguez-Salas N, Salgado M, Salud A, Feliu J. Clinical guideline SEOM: hepatocellular carcinoma. Clin Transl Oncol 2015;17:988-95. [PMID: 26607931 DOI: 10.1007/s12094-015-1451-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
138 Enomoto H, Tao L, Eguchi R, Sato A, Honda M, Kaneko S, Iwata Y, Nishikawa H, Imanishi H, Iijima H, Tsujimura T, Nishiguchi S. The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis. Sci Rep 2017;7:12189. [PMID: 28939881 DOI: 10.1038/s41598-017-12414-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
139 He XX, Zhang YN, Yan JW, Yan JJ, Wu Q, Song YH. CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo. Tumour Biol 2016;37:807-15. [PMID: 26250460 DOI: 10.1007/s13277-015-3857-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
140 Gnocchi D, Del Coco L, Girelli CR, Castellaneta F, Cesari G, Sabbà C, Fanizzi FP, Mazzocca A. 1H-NMR metabolomics reveals a multitarget action of Crithmum maritimum ethyl acetate extract in inhibiting hepatocellular carcinoma cell growth. Sci Rep 2021;11:1259. [PMID: 33441568 DOI: 10.1038/s41598-020-78867-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
141 Fang KC, Su CW, Chiou YY, Lee PC, Chiu NC, Liu CA, Chen PH, Kao WY, Huang YH, Huo TI, Hou MC, Lin HC, Wu JC. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: a propensity score matching analysis. Eur Radiol. 2017;27:2600-2609. [PMID: 27678133 DOI: 10.1007/s00330-016-4604-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
142 Wang S, Deng Y, Yu X, Zhang XW, Huo CL, Sun ZG, Chang H. Prognostic significance of preoperative systemic inflammatory biomarkers in patients with hepatocellular carcinoma after microwave ablation and establishment of a nomogram. Sci Rep 2021;11:13814. [PMID: 34226605 DOI: 10.1038/s41598-021-93289-3] [Reference Citation Analysis]
143 Bogaerts E, Heindryckx F, Vandewynckel YP, Van Grunsven LA, Van Vlierberghe H. The roles of transforming growth factor-β, Wnt, Notch and hypoxia on liver progenitor cells in primary liver tumours (Review). Int J Oncol. 2014;44:1015-1022. [PMID: 24504124 DOI: 10.3892/ijo.2014.2286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
144 Liu P, Atkinson SJ, Akbareian SE, Zhou Z, Munsterberg A, Robinson SD, Bao Y. Sulforaphane exerts anti-angiogenesis effects against hepatocellular carcinoma through inhibition of STAT3/HIF-1α/VEGF signalling. Sci Rep 2017;7:12651. [PMID: 28978924 DOI: 10.1038/s41598-017-12855-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
145 Mathewos M. Pathological and Cytological Studies on Hepatocellular Carcinoma in Cattle Slaughtered at Bishoftu Elfora Abattoir, Central Ethiopia. Vet Med Int 2021;2021:6649172. [PMID: 34035888 DOI: 10.1155/2021/6649172] [Reference Citation Analysis]
146 Ye QW, Pang SJ, Yang N, Zhang HB, Fu Y, Lin B, Yang GS. Safety and Efficacy of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma (3-5 cm): a Propensity Score Matching Cohort Study. J Gastrointest Surg 2019;23:1549-58. [PMID: 31197690 DOI: 10.1007/s11605-019-04229-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Lee JE, Bae SH, Choi JY, Yoon SK, You YK, Lee MA. Epirubicin, Cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol 2014; 20(1): 235-241 [PMID: 24415877 DOI: 10.3748/wjg.v20.i1.235] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
148 Yang N, Bertoletti A. Advances in therapeutics for chronic hepatitis B. Hepatol Int 2016;10:277-85. [PMID: 26363922 DOI: 10.1007/s12072-015-9661-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
149 Liu L, Zhao Y, Jia J, Chen H, Bai W, Yang M, Yin Z, He C, Zhang L, Guo W, Niu J, Yuan J, Cai H, Xia J, Fan D, Han G. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization. Sci Rep 2016;6:19851. [PMID: 26831408 DOI: 10.1038/srep19851] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
150 Zhu X, Wu X, Cheng J, Liao H, Di X, Li L, Li R, Zhou Y, Zhang X. Dalbinol, a rotenoid from Amorpha fruticosa L., exerts anti-proliferative activity by facilitating β-catenin degradation in hepatocellular carcinoma cells. Oncotarget 2017;8:47755-66. [PMID: 28548956 DOI: 10.18632/oncotarget.17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
151 Zhu W, Doubleday PF, Butrin A, Weerawarna PM, Melani RD, Catlin DS, Dwight TA, Liu D, Kelleher NL, Silverman RB. Remarkable and Unexpected Mechanism for (S)-3-Amino-4-(difluoromethylenyl)cyclohex-1-ene-1-carboxylic Acid as a Selective Inactivator of Human Ornithine Aminotransferase. J Am Chem Soc 2021;143:8193-207. [PMID: 34014654 DOI: 10.1021/jacs.1c03572] [Reference Citation Analysis]
152 Kohli A, Murphy AA, Agarwal C, Shivakumar B, Kottilil S, Polis MA, Subramanian GM, Midha V, Goyal O, Desai S, Sood A, Shah S. HCC surveillance results in earlier HCC detection: results from an Indian cohort. Springerplus 2014;3:610. [PMID: 25392781 DOI: 10.1186/2193-1801-3-610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
153 Zhang J, Zhang D, Zhao Q, Qi J, Li X, Qin C. A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic biomarker in hepatocellular carcinoma. Cancer Med 2018. [PMID: 29790663 DOI: 10.1002/cam4.1565] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
154 Wei W, Jian PE, Li SH, Guo ZX, Zhang YF, Ling YH, Lin XJ, Xu L, Shi M, Zheng L, Chen MS, Guo RP. Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety. Cancer Commun (Lond) 2018;38:61. [PMID: 30305149 DOI: 10.1186/s40880-018-0331-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 9.7] [Reference Citation Analysis]
155 Zhang J, Li H, Gao D, Zhang B, Zheng M, Lun M, Wei M, Duan R, Guo M, Hua J, Liu Q, Bai J, Liu H, Zheng J, Yao H. A prognosis and impact factor analysis of DC-CIK cell therapy for patients with hepatocellular carcinoma undergoing postoperative TACE. Cancer Biol Ther. 2018;19:475-483. [PMID: 29400599 DOI: 10.1080/15384047.2018.1433501] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
156 Shah C, Mramba LK, Bishnoi R, Bejjanki H, Chhatrala HS, Chandana SR. Survival differences among patients with hepatocellular carcinoma based on the stage of disease and therapy received: pre and post sorafenib era. J Gastrointest Oncol 2017;8:789-98. [PMID: 29184682 DOI: 10.21037/jgo.2017.06.16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
157 Singh A, Nyankima AG, Anthony Phipps M, Chaplin V, Dayton PA, Caskey C. Improving the heating efficiency of high intensity focused ultrasound ablation through the use of phase change nanodroplets and multifocus sonication. Phys Med Biol 2020;65:205004. [PMID: 32438353 DOI: 10.1088/1361-6560/ab9559] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
158 Fan Y, Hu D, Feng B, Wang W. The NQO1 C609T polymorphism and hepatocellular carcinoma risk. Tumour Biol 2014;35:7343-50. [PMID: 24532470 DOI: 10.1007/s13277-014-1712-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
159 Testino G, Leone S, Borro P. Alcohol and hepatocellular carcinoma: A review and a point of view. World J Gastroenterol 2014; 20(43): 15943-15954 [PMID: 25473148 DOI: 10.3748/wjg.v20.i43.15943] [Cited by in CrossRef: 63] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
160 Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73. [PMID: 28097502 DOI: 10.1007/s13304-017-0414-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
161 Huang JL, Ren TY, Cao SW, Zheng SH, Hu XM, Hu YW, Lin L, Chen J, Zheng L, Wang Q. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget 2015;6:33791-804. [PMID: 26393879 DOI: 10.18632/oncotarget.5667] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 11.0] [Reference Citation Analysis]
162 Gnocchi D, Kapoor S, Nitti P, Cavalluzzi MM, Lentini G, Denora N, Sabbà C, Mazzocca A. Novel lysophosphatidic acid receptor 6 antagonists inhibit hepatocellular carcinoma growth through affecting mitochondrial function. J Mol Med (Berl) 2020;98:179-91. [PMID: 31863151 DOI: 10.1007/s00109-019-01862-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
163 Knudsen ES, Gopal P, Singal AG. The changing landscape of hepatocellular carcinoma: etiology, genetics, and therapy. Am J Pathol. 2014;184:574-583. [PMID: 24388934 DOI: 10.1016/j.ajpath.2013.10.028] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
164 Fu QH, Zhang Q, Bai XL, Hu QD, Su W, Chen YW, Su RG, Liang TB. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140:1429-1440. [PMID: 24770582 DOI: 10.1007/s00432-014-1684-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
165 Michal K, Sau M, Tamara GMH, Long JR. A better route to ALPPS: minimally invasive vs open ALPPS. Surg Endosc 2020;34:2379-89. [PMID: 32274625 DOI: 10.1007/s00464-020-07437-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
166 Li X, Hu J, Gu B, Paul ME, Wang B, Yu Y, Feng Z, Ma Y, Wang X, Chen H. Animal model of intrahepatic metastasis of hepatocellular carcinoma: establishment and characteristic. Sci Rep 2020;10:15199. [PMID: 32939004 DOI: 10.1038/s41598-020-72110-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
167 Chang CW, Lo JF, Wang XW. Roles of mitochondria in liver cancer stem cells. Differentiation 2019;107:35-41. [PMID: 31176254 DOI: 10.1016/j.diff.2019.04.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
168 Kumar A, Acharya SK, Singh SP, Saraswat VA, Arora A, Duseja A, Goenka MK, Jain D, Kar P, Kumar M, Kumaran V, Mohandas KM, Panda D, Paul SB, Ramachandran J, Ramesh H, Rao PN, Shah SR, Sharma H, Thandassery RB; (The INASL Task-Force on Hepatocellular Carcinoma). The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol 2014;4:S3-S26. [PMID: 25755608 DOI: 10.1016/j.jceh.2014.04.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 4.6] [Reference Citation Analysis]
169 Jiang YQ, Wang ZX, Deng YN, Yang Y, Wang GY, Chen GH. Efficacy of Hepatic Resection vs. Radiofrequency Ablation for Patients With Very-Early-Stage or Early-Stage Hepatocellular Carcinoma: A Population-Based Study With Stratification by Age and Tumor Size. Front Oncol. 2019;9:113. [PMID: 30863723 DOI: 10.3389/fonc.2019.00113] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
170 Jiang C, Wang Z, Xu Q, Wu X, Ding Y. Inferior Right Hepatic Vein-preserving Major Right Hepatectomy for Hepatocellular Carcinoma in Patients with Significant Fibrosis or Cirrhosis. World J Surg. 2014;38:159-167. [PMID: 24081537 DOI: 10.1007/s00268-013-2240-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
171 Bayo J, Fiore E, Aquino JB, Malvicini M, Rizzo M, Peixoto E, Andriani O, Alaniz L, Piccioni F, Bolontrade M. Increased migration of human mesenchymal stromal cells by autocrine motility factor (AMF) resulted in enhanced recruitment towards hepatocellular carcinoma. PLoS One. 2014;9:e95171. [PMID: 24736611 DOI: 10.1371/journal.pone.0095171] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
172 Wu JY, Wang ZX, Zhang G, Lu X, Qiang GH, Hu W, Ji AL, Wu JH, Jiang CP. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy. Int J Nanomedicine 2018;13:1265-80. [PMID: 29551896 DOI: 10.2147/IJN.S156328] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
173 Xia C, Zeng H, Zheng Y. Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis. Mol Med Rep 2020;21:989-98. [PMID: 32016465 DOI: 10.3892/mmr.2020.10936] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
174 Li MX, Zhao H, Bi XY, Li ZY, Yao XS, Li H, Huang Z, Han Y, Zhou JG, Zhao JJ, Zhang YF, Zhao DB, Cai JQ. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area. Oncotarget 2016;7:86630-47. [PMID: 27880930 DOI: 10.18632/oncotarget.13428] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
175 Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma. Gut Liver. 2015;9:94-102. [PMID: 25071067 DOI: 10.5009/gnl14009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
176 Ladju RB, Pascut D, Massi MN, Tiribelli C, Sukowati CHC. Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma. Oncotarget 2018;9:2951-61. [PMID: 29416827 DOI: 10.18632/oncotarget.23359] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
177 Saitta C, Raffa G, Alibrandi A, Brancatelli S, Lombardo D, Tripodi G, Raimondo G, Pollicino T. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients. Medicine (Baltimore) 2017;96:e7266. [PMID: 28658121 DOI: 10.1097/MD.0000000000007266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
178 Huang J, Liu FC, Li L, Zhou WP, Jiang BG, Pan ZY. Nomograms to predict the long-time prognosis in patients with alpha-fetoprotein negative hepatocellular carcinoma following radical resection. Cancer Med 2020;9:2791-802. [PMID: 32096346 DOI: 10.1002/cam4.2944] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
179 Cheng L, Du X, Wang Z, Ju J, Jia M, Huang Q, Xing Q, Xu M, Tan Y, Liu M, Du P, Su L, Wang S. Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol 2014;61:1297-303. [PMID: 25016226 DOI: 10.1016/j.jhep.2014.07.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
180 Ping Z, Jun X, Yan W, Jun Z. Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment. Eur J Integr Med 2020;:101215. [PMID: 33042292 DOI: 10.1016/j.eujim.2020.101215] [Reference Citation Analysis]
181 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Si T, Chen Y, Ma D, Gong X, Yang K, Guan R, Peng C. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials. Scand J Gastroenterol. 2016;51:1512-1519. [PMID: 27598831 DOI: 10.1080/00365521.2016.1216588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
183 Cauble S, Abbas A, Balart L, Bazzano L, Medvedev S, Shores N. United States women receive more curative treatment for hepatocellular carcinoma than men. Dig Dis Sci. 2013;58:2817-2825. [PMID: 23812858 DOI: 10.1007/s10620-013-2731-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
184 Guillot C, Favaudon V, Herceg Z, Sagne C, Sauvaigo S, Merle P, Hall J, Chemin I. PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. BMC Cancer. 2014;14:603. [PMID: 25139788 DOI: 10.1186/1471-2407-14-603] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
185 Bacigalupo ML, Manzi M, Rabinovich GA, Troncoso MF. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8831-8849 [PMID: 24379606 DOI: 10.3748/wjg.v19.i47.8831] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
186 Bai T, Chen J, Xie ZB, Wu FX, Wang SD, Liu JJ, Li LQ. The efficacy and safety of postoperative adjuvant transarterial embolization and radiotherapy in hepatocellular carcinoma patients with portal vein tumor thrombus. Onco Targets Ther. 2016;9:3841-3848. [PMID: 27390524 DOI: 10.2147/ott.s104307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
187 Yoon HI, Seong J. Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer 2016;5:139-51. [PMID: 27386432 DOI: 10.1159/000367762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
188 Santambrogio R, Chiang J, Barabino M, Meloni FM, Bertolini E, Melchiorre F, Opocher E. Comparison of Laparoscopic Microwave to Radiofrequency Ablation of Small Hepatocellular Carcinoma (≤3 cm). Ann Surg Oncol 2017;24:257-63. [PMID: 27581608 DOI: 10.1245/s10434-016-5527-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
189 Ellebrecht DB, Theisen-Kunde D, Kuempers C, Keck T, Kleemann M, Wolken H. Analysis of laparoscopic laser liver resection in standardized porcine model. Surg Endosc 2018;32:4966-72. [PMID: 29869079 DOI: 10.1007/s00464-018-6258-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
190 Moore A, Cohen-Naftaly M, Benjaminov O, Braun M, Issachar A, Mor E, Tovar A, Sarfaty M, Gordon N, Stemmer SM. Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience. J Cancer 2016;7:883-9. [PMID: 27313777 DOI: 10.7150/jca.14721] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
191 杨薇. 影像引导射频消融治疗较大肝癌的现状及前景. 世界华人消化杂志 2015; 23(30): 4771-4777 [DOI: 10.11569/wcjd.v23.i30.4771] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Chiang J, Wang P, Brace CL. Computational modelling of microwave tumour ablations. Int J Hyperthermia 2013;29:308-17. [PMID: 23738698 DOI: 10.3109/02656736.2013.799295] [Cited by in Crossref: 54] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
193 Ravi S, Singal AK. Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer. Core Evid. 2014;9:81-87. [PMID: 25114628 DOI: 10.2147/ce.s48626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
194 Cheng Z, Yang P, Qu S, Zhou J, Yang J, Yang X, Xia Y, Li J, Wang K, Yan Z. Risk factors and management for early and late intrahepatic recurrence of solitary hepatocellular carcinoma after curative resection. HPB (Oxford). 2015;17:422-427. [PMID: 25421805 DOI: 10.1111/hpb.12367] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
195 Zigmond E, Ben Ya'acov A, Lee H, Lichtenstein Y, Shalev Z, Smith Y, Zolotarov L, Ziv E, Kalman R, Le HV, Lu H, Silverman RB, Ilan Y. Suppression of Hepatocellular Carcinoma by Inhibition of Overexpressed Ornithine Aminotransferase. ACS Med Chem Lett 2015;6:840-4. [PMID: 26288681 DOI: 10.1021/acsmedchemlett.5b00153] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
196 Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C, Giannelli G. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II. PLoS One. 2013;8:e67109. [PMID: 23826206 DOI: 10.1371/journal.pone.0067109] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 7.5] [Reference Citation Analysis]